Metabolic reprogramming represents a characteristic feature of malignancy,which can be exploited for the diagnosis,monitoring,and treatment of cancer.Dysregulation of the L-arginine metabolic pathway has been consistently detected in tumors,and DDAH1 is involved in the metabolism of arginine through the DDAH1/ADMA/NO pathway,by affecting tumor progression.This review primarily elucidates the DDAH1 metabolic pathway,the regulation of DDAH1,and the research progress in DDAH1 with respect to tumors.Additionally,the latest progress in the clinical translation of DDAH1-targeted molecular inhibitors is discussed,which provides novel insights for cancer treatment.
维普
万方数据